Stifel Nicolaus Reiterates Buy Rating for Krystal Biotech (NASDAQ:KRYS)

Stifel Nicolaus restated their buy rating on shares of Krystal Biotech (NASDAQ:KRYS - Free Report) in a research note issued to investors on Tuesday morning, Benzinga reports. They currently have a $204.00 target price on the stock, up from their previous target price of $178.00.

Several other research firms have also recently weighed in on KRYS. Guggenheim boosted their price target on Krystal Biotech from $130.00 to $175.00 and gave the stock a buy rating in a report on Tuesday, February 27th. William Blair restated an outperform rating on shares of Krystal Biotech in a report on Tuesday, February 27th. Finally, Citigroup boosted their price target on Krystal Biotech from $160.00 to $195.00 and gave the stock a buy rating in a report on Tuesday, February 27th. Nine analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of Buy and a consensus target price of $164.22.

Krystal Biotech Trading Up 0.2 %

NASDAQ KRYS traded up $0.34 during trading on Tuesday, hitting $170.09. 200,430 shares of the company's stock were exchanged, compared to its average volume of 376,492. The company has a market cap of $4.85 billion, a PE ratio of 2,126.39 and a beta of 0.85. The stock's 50 day moving average price is $156.57 and its two-hundred day moving average price is $129.21. Krystal Biotech has a fifty-two week low of $82.09 and a fifty-two week high of $189.97.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its quarterly earnings results on Monday, February 26th. The company reported $0.30 earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.82. The firm had revenue of $42.14 million for the quarter, compared to the consensus estimate of $27.43 million. During the same quarter last year, the firm posted ($1.25) earnings per share. Analysts forecast that Krystal Biotech will post 1.61 earnings per share for the current fiscal year.

Insider Activity at Krystal Biotech

In other Krystal Biotech news, CAO Kathryn Romano sold 2,500 shares of the stock in a transaction that occurred on Monday, January 22nd. The stock was sold at an average price of $130.00, for a total transaction of $325,000.00. Following the transaction, the chief accounting officer now directly owns 12,556 shares in the company, valued at approximately $1,632,280. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other Krystal Biotech news, CAO Kathryn Romano sold 2,500 shares of the stock in a transaction that occurred on Monday, January 22nd. The stock was sold at an average price of $130.00, for a total transaction of $325,000.00. Following the transaction, the chief accounting officer now directly owns 12,556 shares in the company, valued at approximately $1,632,280. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $170.96, for a total value of $4,274,000.00. Following the transaction, the insider now owns 1,550,882 shares in the company, valued at $265,138,786.72. The disclosure for this sale can be found here. Insiders have sold 40,587 shares of company stock worth $6,535,591 over the last ninety days. Insiders own 14.10% of the company's stock.

Hedge Funds Weigh In On Krystal Biotech

A number of institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. boosted its holdings in shares of Krystal Biotech by 1.5% during the 4th quarter. Vanguard Group Inc. now owns 2,435,774 shares of the company's stock worth $302,182,000 after buying an additional 35,632 shares in the last quarter. BlackRock Inc. raised its position in shares of Krystal Biotech by 1.0% during the first quarter. BlackRock Inc. now owns 1,716,095 shares of the company's stock worth $137,391,000 after purchasing an additional 16,499 shares during the period. State Street Corp raised its position in shares of Krystal Biotech by 52.3% during the first quarter. State Street Corp now owns 1,068,656 shares of the company's stock worth $71,108,000 after purchasing an additional 366,855 shares during the period. Jennison Associates LLC raised its position in shares of Krystal Biotech by 112.5% during the fourth quarter. Jennison Associates LLC now owns 724,344 shares of the company's stock worth $89,862,000 after purchasing an additional 383,495 shares during the period. Finally, First Light Asset Management LLC raised its position in shares of Krystal Biotech by 5.6% during the first quarter. First Light Asset Management LLC now owns 717,936 shares of the company's stock worth $47,771,000 after purchasing an additional 37,766 shares during the period. 86.29% of the stock is currently owned by institutional investors.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).